Elevance Health, Inc. (NYSE:ELV) is one of the Most Undervalued Long Term Stocks to Buy According to Analysts. On March 11, Mizuho analyst Ann Hynes lowered the firm’s price target on Elevance Health, Inc. (NYSE:ELV) from $413 to $350 and maintained a Buy rating on the stock.

​The analyst noted that the reduced price target reflects the company’s reaffirmed guidance amid the ongoing Centers for Medicare and Medicaid Services scrutiny. Hynes said in a research note that the company disclosed that the Centers for Medicare and Medicaid Services (CMS) sanctions target historical data submission issues. These involve noncompliance in reporting diagnosis codes through improper methods, potentially leading to enrollment suspensions.

​Despite the challenges, the company reiterated its 2026 outlook at a competitor event, stating the sanctions relate only to past processes and do not affect current risk-adjustment operations. Hynes noted that the current 2026 estimates already factor in any financial impacts, hence she reiterated a Buy rating on the stock.

​Elevance Health, Inc. (NYSE:ELV) is a health company that operates through the following segments: Health Benefits, CarelonRx, Carelon Services, and Corporate and Other. The Health Benefits segment offers a range of health plans and services, while the CarelonRx segment manages pharmacy services. The Carelon Services segment offers various healthcare-related services by integrating behavioral, physical, pharmacy, and social services.

While we acknowledge the potential of ELV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.